Environmental Risk Assessment Services
Environmental Risk Assessment (ERA) Services for Human and Animal Drug Products
Ensuring Regulatory Compliance and Environmental Risk Assessment Services with Zenovel
At Zenovel, we offer specialized Environmental Risk Assessment services for both human and veterinary drug products. Our comprehensive approach evaluates the potential environmental impacts that may result from the use, storage, and disposal of pharmaceuticals, ensuring compliance with international regulatory frameworks while protecting ecosystems and public health.
- Era for Human Medical Products
- Zenovel’s Environmental Risk Assessment Services for human medicines follow the stepwise approach outlined in EU Directive 2001/83/EC:
- Phase I: Estimation of the Predicted Environmental Concentration (PEC) to determine environmental exposure levels.
- Phase II: A more detailed assessment is conducted if Phase I indicates potential risk.
- An ERA is mandatory for all new Marketing Authorization Applications (MAAs) in Europe, including generics, in line with EMA guideline CPMP/SWP/4447/00 (2006) and its supporting Q&A guidance (EMEA/CHMP/SWP/44609/2010 Rev.1, 2016). In the United States, Environmental Assessments (EAs) are required for NDAs, ANDAs, INDs, and other regulatory submissions.
ERA for Veterinary Medicinal Products
For veterinary pharmaceuticals, Zenovel conducts ERAs with a focus on the environmental release of active substances via excretion from treated animals, assessing potential impacts on non-target organisms and ecological systems.
Our ERA Service Portfolio
Zenovel offers end-to-end support across all stages of the Environmental Risk Assessment Services process:
- Tier I and Tier II ERA Assessments for human and veterinary drugs
- Preparation of ERA Waiver Justifications for generic product submissions
- Regulatory Interactions with environmental competent authorities
- Persistence, Bioaccumulation, and Toxicity (PBT) Screening
- Preparation of Ecotoxicology Study Summaries in line with ECHA dossier formats
Commitment to Sustainable Compliance
The goal of Zenovel’s ERA services is to assess and reduce the risk of adverse environmental impacts—to human health, biodiversity, and ecosystems—while supporting the safe use, storage, and disposal of drug products. We ensure this information is clearly communicated in Summary of Product Characteristics (SmPC) documents and product labeling.
-
Partner with Zenovel
- With a strong foundation in regulatory expertise and scientific rigor, Zenovel is your trusted partner for ERA compliance and consultation. For any questions regarding ERA submissions or product-related inquiries from health authorities, our team is ready to assist you. Contact Zenovel today to learn how we can support your product’s environmental safety profile.
- Ensuring compliance and strategic advantage through their extensive knowledge of global regulations and industry standards
People Also Ask (FAQs)
Environmental Risk Assessment (ERA) for pharmaceuticals evaluates the potential impact of medicinal products on the environment. This process analyzes how active pharmaceutical ingredients may affect ecosystems, water systems, and wildlife to ensure environmental safety and regulatory compliance during drug approval.
Regulatory authorities require environmental risk assessment (ERA) to ensure a medicinal product does not pose risks to the environment. It supports approvals in regions like the EU. Zenovel assists by preparing compliant ERA documentation, evaluating environmental impact, and ensuring alignment with global regulatory requirements for successful submissions.
A typical environmental risk assessment for pharmaceuticals includes exposure analysis, environmental fate studies, risk characterization, and environmental impact evaluation. These studies help identify potential ecological risks associated with pharmaceutical substances.
Environmental risk assessment services are typically required during regulatory submissions for new drug applications, marketing authorization applications, and variations involving environmental impact considerations. Regulatory agencies use ERA data to evaluate the environmental safety of medicinal products.
Zenovel provides expert environmental risk assessment services for pharmaceutical companies, including ERA study planning, regulatory documentation preparation, and environmental compliance support. Their team helps ensure that pharmaceutical products meet environmental regulatory requirements for global approvals.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
